CClinicalTrials.gg
Status unknownNCT04547296Updated Aug 19, 2021

Sodium Bicarbonate Ringer's Solution for Preventing and Treating Hyperlactacidemia During Hepatectomy

An interventional study of Sodium Bicarbonate Ringer's Solution in Hyperlactacidemia, sponsored by First Affiliated Hospital Xi'an Jiaotong University. Status unknown at 7 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-19.

Sponsored by First Affiliated Hospital Xi'an Jiaotong University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2021), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
484
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A variety of reasons lead to a sharp increase in lactic acid levels in patients undergoing liver resection, while leading to hyperlactic acidemia, resulting in decreased cardiac output, elevated blood potassium, and response to catecholamines and insulin Damage, increased risk of kidney damage, poor recovery of liver function, decreased immune function, and prolonged hospital stay. Sodium bicarbonate Ringer injection does not contain lactic acid. HCO3- is metabolized by acid-base neutralization in body fluids, and 90% is CO2 The form is excreted from the body by breathing, and only 10% HCO3- is metabolized by the kidney, without the burden of liver metabolism. Physiological concentration of Cl- avoids perchloric acidosis and kidney damage; physiological concentration of Ca2+ and Mg2+ help maintain the body's electrolyte balance and reduce stress-related arrhythmia.The smooth development of this study will help refine the intraoperative fluid management strategy, improve the patient's intraoperative tissue perfusion, maintain the body's acid-base and electrolyte balance, reduce postoperative kidney damage, and improve the patient's quality of life.

Read the detailed description

This study intends to carry out a high-quality clinical research with design specifications, large sample, multi-center, randomized and controlled methods. From October 9, 2020 to October 9, 2022, participants undergoing hepatectomy surgery under general anesthesia will be recruited. Participants will be randomly assigned, in a 1:1 ratio, to receive Sodium bicarbonate Ringer's solution or control (Acetate Ringer's solution). The randomization sequence will be computer-generated, and randomization will be performed in blocks and will be stratified according to participating center. After entering the operating room, the two groups were pre-dilated with sodium bicarbonate Ringer or acetate Ringer (30 min, 8 ml/kg). After the operation started, the two groups of participants were maintained with 4-5 ml/kg/h Ringer's solution during the operation. Blood gas index (but are not limited to these data) at intraoperative will be recorded. At the same time, other dates will be recorded.The participation of each patient is scheduled for 1 month.

02

Conditions studied

  • Hyperlactacidemia

Browse trials for

Keywords

  • hyperlactacidemia
  • Sodium bicarbonate Ringer's solution
  • Acetate Ringer's solution
  • hepatectomy
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Patients for selective liver surgery under general anesthesia
  2. Age > 18 year,BMI 18 - 40 kg/m2,American society of Anesthesiologists (ASA) grade are between I - III
  3. Ability to understand, sign informed consent and cooperate with the intervention and evaluation

Exclusion criteria

Exclusion Criteria:

  1. Abnormal renal function:blood creatinine (Cr) and / or urea nitrogen (BUN)> upper limit of normal value; Patients with underlying kidney disease; patients with congenital kidney malformations.
  2. In patients with respiratory failure, arterial blood oxygen partial pressure (PaO2) \< 60 mmHg, or accompanied by carbon dioxide partial pressure (PaCO2)> 50mmHg; blood oxygen saturation (SpO2) \< 90%.
  3. A history of myocardial infarction within 6 months before the screening period; history of severe circulatory or respiratory diseases; history of autoimmune diseases; patients with mental illness or neurological disorders that cannot be expressed exactly; patients with a history of epilepsy; patients with pulmonary edema or congestive heart failure.
  4. Severe hypercalcemia (Ca2+ > 2.75 mmol/L), hypernatremia (Na+ > 155 mmol/L), hyperkalemia (K+ > 5.5 mmol/L), hyperchloremia (Cl- > 110 mmol/L), Hypermagnesium (Mg2+ > 1.25 mmol/L).
  5. Patients with a history of hypothyroidism; pregnant or lactating women.
  6. Patients with a history of adverse blood transfusion reactions; those who refuse blood transfusions.
  7. Participation in other clinical studies within 3 months before admission to this study.
  8. The investigator considers it unsuitable for inclusion.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
484 participants (estimated)

Study arms

  • Experimental
    BRS group

    After entering the operating room, this group were pre-dilated with sodium bicarbonate ringer's solution (30 min, 8 ml/kg), and maintained with 4-5 ml/kg/h sodium bicarbonate ringer's solution during the operation.

    Drug: Sodium Bicarbonate Ringer's Solution

  • Experimental
    ARS group

    After entering the operating room, this group were pre-dilated with acetate ringer ringer's solution (30 min, 8 ml/kg), and maintained with 4-5 ml/kg/h acetate ringer's solution during the operation.

    Drug: Sodium Bicarbonate Ringer's Solution

Interventions

  • DrugSodium Bicarbonate Ringer's Solution

    After the participants enter the operating room, radial artery puncture and catheterization were performed. The blood gas in the non-oxygen state was used as the basic value. A peripheral venous access was established in one upper limb, and the two groups were pre-dilated with sodium bicarbonate Ringer's solution or acetate Ringer's solution (30 min, 8 ml/kg). For laparoscopic surgery, adjust the PaCO2 value to 35-45 mmHg again 10 minutes after the establishment of the pneumoperitoneum. After the operation started, the two groups of participants were maintained with 4-5 ml/kg/h Ringer's solution during the operation. Blood gas was measured every hour after tracheal intubation during the operation, and the last blood gas was measured when the skin was sutured. When the blood gas pH \<7.2, 5% sodium bicarbonate injection was given to correct it.

    Also known as: Acetate Ringer's Solution

05

What researchers measure

Primary outcomes

  1. Incidence of intraoperative hyperlactacidemia

    Diagnostic criteria: Lac ≥ 2 mmol/L, pH ≤ 7.35, HCO3- ≤ 20 mmol/L, PaCO2 \<50 mmHg

    Time frame: During the operation

Secondary outcomes

  1. The incidence of blood gas index disorder

    Blood gas was monitored every hour during the operation and the incidence of intraoperative blood gas index disorder was recorded

    Time frame: During the operation

  2. Incidence of postoperative acute kidney injury

    The incidence of acute kidney injury within 48h after surgery was recorded

    Time frame: Day 2 after the operation

  3. Rate of postoperative complications

    postoperative complications: cardiovascular complications; pulmonary complications; infection complications; other complications

    Time frame: Day 30 after the operation

06

Study locations

7 of 7 sites recruiting
  • The First Hospital of Lanzhou University
    Lanzhou, Gansu 0931730000, China
    • Yatao Liu, MD · Contact · 0086-18152107860
    • Yatao Liu, MD · Sub investigator
    Recruiting
  • Henan Cancer Hospital
    Zhengzhou, Henan 0371450003, China
    • Xihua Lu, MD · Contact · 0086-18539965618
    • Xihua Lu, MD · Sub investigator
    Recruiting
  • Henan Provincial People's Hospital
    Zhengzhou, Henan 0371450008, China
    • jiaqiang zhang, PHD · Contact · 0086-13937121360
    • jiaqiang zhang, PHD · Sub investigator
    Recruiting
  • Qinghai University Affiliated Hospita
    Xining, Qinghai 0971810001, China
    • Zhen Jia, MD · Contact · 0086-13519702706
    • Zhen Jia, MD · Sub investigator
    Recruiting
  • Shaanxi Provincial People's Hospital
    Xi'an, Shaanxi 029710068, China
    • Rui Yang, MD · Contact · 0086-13572135219
    • Rui Yang, MD · Sub investigator
    Recruiting
  • People's Hospital of Xinjiang Uygur Autonomous Region
    Ürümqi, Xinjiang 0991830001, China
    • Guiping Xu, PHD · Contact · 0086-13669988366
    • Guiping Xu, PHD · Sub investigator
    Recruiting
  • The First Affiliated Hospital of Xinjiang Medical University
    Ürümqi, Xinjiang 0991830054, China
    • Yi Hong, PHD · Contact · 0086-13009620188
    • Yi Hong, PHD · Sub investigator
    Recruiting
07

Registry details

Key details

Study ID
NCT04547296
Lead sponsor
First Affiliated Hospital Xi'an Jiaotong University
Collaborators
Henan Provincial People's Hospital, Henan Cancer Hospital, LanZhou University, Affiliated Hospital of Qinghai University, Shaanxi Provincial People's Hospital, First Affiliated Hospital of Xinjiang Medical University, People's Hospital of Xinjiang Uygur Autonomous Region
Responsible party
Sponsor
First posted
Sep 14, 2020
Start date
Apr 28, 2021
Primary completion
Oct 9, 2022 (estimated)
Completion
Mar 30, 2023 (estimated)
Last update
Aug 19, 2021

Study contacts

Wei Gao, PHD
Contact
gaowei2906@xjtufh.edu.cn
0086-15209225834
Qiang Wang, PHD
Contact
dr.wangqiang@139.com
0086-18049286968
Qiang Wang, PHD
study chair · First Affiliated Hospital Xi'an Jiaotong University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion